m1774
Small moleculeexperimental
Clinical trial activity
15 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 19, 2019 (NCT04170153)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 2
- Lymphoma · Phase 1/Phase 2
- Mutation · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
Mechanism of action
- ATR/ATRIPINHIBITOR
ATR/ATRIP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cncc1-c1c(F)cncc1NC(=O)c1c(N)nn2cc(F)cnc12- Mol. weight
- 370.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314933 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06518564 | Phase 2 | Jan 31, 2025 | Harvard University, Merck Serono |
| NCT06596473 | Phase 1 | Oct 3, 2024 | BeOne Medicines |
| NCT06424717 | Phase 2 | Aug 16, 2024 | Merck KGaA, Merck Serono |
| NCT06421935 | Phase 1 | Aug 7, 2024 | Merck KGaA, Merck Serono |
| NCT06337630 | Phase 1 | Jun 15, 2024 | Curie Institute, Merck, ProLynx LLC |
| NCT05950464 | Phase 1 | May 27, 2024 | National Cancer Institute (NCI), NRG Oncology |
| NCT05986071 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Institut Paoli-Calmettes, Merck, National Cancer Institute, France |
| NCT06308263 | Phase 1 | Mar 25, 2024 | Merck KGaA |
| NCT05687136 | Phase 1 | Feb 25, 2024 | Harvard University, National Cancer Institute (NCI) |
| NCT05947500 | Phase 2 | Dec 18, 2023 | National Cancer Institute (NCI), University of Washington |
| NCT05828082 | Phase 2 | Oct 16, 2023 | Harvard University, National Cancer Institute (NCI) |
| NCT05691491 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2023 | National Cancer Institute (NCI), Yale University |
| NCT05882734 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2023 | Merck KGaA, Merck Serono |
| NCT05396833 | Phase 1 | Jun 7, 2022 | Merck KGaA, Merck Serono |
| NCT04170153 | Phase 1 | Nov 19, 2019 | Merck KGaA, Merck Serono |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 6 | 1 | 2 | 2019 |
| Merck Serono | For profit | 6 | 5 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 5 | 5 | 2 | 2023 |
| Harvard University | Academic/Hospital | 3 | 1 | 2 | 2023 |
| Merck | For profit | 2 | 0 | 2 | 2024 |
| BeOne Medicines | For profit | 1 | 1 | 1 | 2024 |
| Curie Institute | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2024 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| ProLynx LLC | For profit | 1 | 0 | 1 | 2024 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2023 |
13 organizations
Page 1 / 1